KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $325.1 million.

  • Alnylam Pharmaceuticals' Cash from Operations rose 64383.74% to $325.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.9 million, marking a year-over-year increase of 37009.64%. This contributed to the annual value of -$8.3 million for FY2024, which is 10798.03% down from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Cash from Operations is $325.1 million, which was up 64383.74% from $153.7 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Cash from Operations peaked at $359.4 million during Q3 2023, and registered a low of -$235.7 million during Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Cash from Operations averaged around -$38.2 million, with its median value being -$115.3 million (2022).
  • In the last 5 years, Alnylam Pharmaceuticals' Cash from Operations plummeted by 21771.1% in 2024 and then skyrocketed by 64383.74% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Cash from Operations (Quarter) stood at -$150.1 million in 2021, then rose by 12.1% to -$132.0 million in 2022, then surged by 77.42% to -$29.8 million in 2023, then tumbled by 217.71% to -$94.7 million in 2024, then soared by 443.44% to $325.1 million in 2025.
  • Its Cash from Operations was $325.1 million in Q3 2025, compared to $153.7 million in Q2 2025 and -$118.3 million in Q1 2025.